Privigen Approval History

Privigen is an immune globulin intravenous (human), 10% liquid indicated for treatment of primary immunodeficiency and chronic immune thrombocytopenic purpura.

FDA Approval History for Privigen

DateArticle
Apr 19, 2010Approval CSL Behring Receives FDA Approval to Extend Shelf Life for Privigen from 24 to 36 Months
Jul 27, 2007Approval CSL Behring Announces FDA Approval of Privigen-- First Proline-Stabilized 10 Percent Liquid IVIg

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web3)